DJIA 16,938.57 -145.23 -0.85%
NASDAQ 4,447.04 -25.07 -0.56%
S&P 500 1,978.19 -9.79 -0.49%
market minute promo

Roche Holding Ltd. (ADR) (NASDAQOTH: RHHBY)

36.91 -0.33 (-0.89%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

RHHBY $36.94 -0.81%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $37.01
Previous Close $37.24
Daily Range $36.83 - $37.07
52-Week Range $30.48 - $38.71
Market Cap $207.5B
P/E Ratio 0.00
Dividend (Yield) $0.00 (2.5%)
Volume 246,793
Average Daily Volume 591,589
Current FY EPS $2.05

Sector

Healthcare

Industry

Pharmaceuticals

Roche Holding Ltd. (ADR) (RHHBY) Description

Website:

News & Commentary Rss Feed

Exelixis Sees Success in Melanoma Treatment With Drug Combination

Partnered with Roche-Genentech, Exelixis should be able to charge more than GlaxoSmithKline for its Melanoma treatment.

Novartis Vs. Everyone: Biologic Knockoffs

5 Pharmas Spending the Most to Develop Drugs: Merck, AstraZeneca, Roche, Bristol, and Lilly

Eli Lilly, Bristol-Myers Squibb, Roche, AstraZeneca, and Merck top the charts.

A Big Pharma Titan Prepares For the Next Generation

Roche looks to maintain leadership into a new generation of oncology.

Is Gilead About to Become an Oncology Powerhouse?

Gilead's (GILD) expanding oncology pipeline could give investors some exciting opportunities.

2 Health Care Partnerships Go Head-To-Head

While the partnership between GlaxoSmithKline (NYSE: GSK) and Ligand (NASDAQ: LGND) seems to be moving forward, the partnership between Roche (OTCMKTS: RHHBY) and PDL (NASDAQ: PDLI) has seemingly reached its end

AstraZeneca’s Alzheimer’s Drug Advances: Now What?

AstraZeneca reported disappointing fourth quarter revenues but showed progress with an Alzheimer's therapy the company has under development.

2 Deaths, 25% Plunge -- And Still A Big Upside

3 Ways Ariad Pharmaceuticals Can Salvage Iclusig

Iclusig has taken quite a few knocks since October, but there are three ways Ariad could rebuild the brand's value and boost shareholder value in the process.

Merck & Co., Inc. Shows Us How to Post Losses and Still Beat the Market

Here’s how to post a 28.6% profit loss, miss estimates, and still beat the S&P 500.

See More RHHBY News...

RHHBY's Top Competitors

RHHBY $36.91 (-0.89%)
Current stock: RHHBY
JNJ $102.01 (-0.19%)
Current stock: JNJ
NVS $88.50 (-0.71%)
Current stock: NVS
GSK $48.31 (-3.53%)
Current stock: GSK